Plasma biomarkers of Alzheimer’s disease improve prediction of cognitive decline in cognitively unimpaired elderly populations
Plasma biomarkers of amyloid, tau and neurodegeneration (ATN) need to be characterized in cognitively unimpaired (CU) elderly individuals. Here, the authors show plasma ATN biomarkers predict clinical deterioration and cognitive decline and show in a simulated clinical trial combining all three biom...
Guardado en:
Autores principales: | Nicholas C. Cullen, Antoine Leuzy, Shorena Janelidze, Sebastian Palmqvist, Anna L. Svenningsson, Erik Stomrud, Jeffrey L. Dage, Niklas Mattsson-Carlgren, Oskar Hansson |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/ed33539191794e8abd8ebdc03d75b61a |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Genetic effects on longitudinal cognitive decline during the early stages of Alzheimer’s disease
por: Atul Kumar, et al.
Publicado: (2021) -
Accelerated inflammatory aging in Alzheimer’s disease and its relation to amyloid, tau, and cognition
por: Nicholas C. Cullen, et al.
Publicado: (2021) -
Publisher Correction: Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
por: Niklas Mattsson-Carlgren, et al.
Publicado: (2021) -
Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies
por: Niklas Mattsson-Carlgren, et al.
Publicado: (2020) -
Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer’s disease
por: Shorena Janelidze, et al.
Publicado: (2020)